ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®.
Company profile
Ticker
CDXC
Exchange
Website
CEO
Robert Fried
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CODY RESOURCES, INC.
SEC CIK
Corporate docs
Subsidiaries
ChromaDex, Inc. • ChromaDex International, Inc. • ChromaDex Analytics, Inc. • ChromaDex Europa B.V. • ChromaDex UK Limited • Asia Pacific Scientific, Inc. • ChromaDex Asia Limited • ChromaDex Asia Pacific Ventures Limited • ChromaDex Trading (Shanghai) Co., Ltd. ...
IRS number
262940963
CDXC stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
ChromaDex Corporation Reports First Quarter 2023 Financial Results
10 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
PRE 14A
Preliminary proxy
19 Apr 23
8-K
Amendments to Articles of Incorporation or Bylaws
17 Mar 23
8-K
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results
8 Mar 23
10-K
2022 FY
Annual report
8 Mar 23
8-K
Departure of Directors or Certain Officers
5 Jan 23
Transcripts
CDXC
Earnings call transcript
2022 Q4
8 Mar 23
CDXC
Earnings call transcript
2022 Q3
2 Nov 22
CDXC
Earnings call transcript
2022 Q2
11 Aug 22
CDXC
Earnings call transcript
2022 Q1
13 May 22
CDXC
Earnings call transcript
2021 Q4
10 Mar 22
CDXC
Earnings call transcript
2021 Q3
4 Nov 21
CDXC
Earnings call transcript
2021 Q2
4 Aug 21
CDXC
Earnings call transcript
2021 Q1
9 May 21
CDXC
Earnings call transcript
2020 Q4
11 Mar 21
CDXC
Earnings call transcript
2020 Q3
4 Nov 20
Latest ownership filings
4
Steven D Rubin
30 May 23
4
Brianna Gerber
17 Feb 23
4
Robert N Fried
17 Feb 23
SC 13G
Societe des Produits Nestle S.A.
19 Oct 22
4
Robert N Fried
3 Oct 22
4
Hoi Shuen Solina Holly Chau
3 Oct 22
3
LI KA SHING
3 Oct 22
SC 13D/A
Champion River Ventures Ltd
3 Oct 22
SC 13D/A
Pioneer Step Holdings Ltd
3 Oct 22
4
Hamed Shahbazi
12 Aug 22
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 23.14 mm | 23.14 mm | 23.14 mm | 23.14 mm | 23.14 mm | 23.14 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 656.00 k | 1.07 mm | (no burn) | 425.67 k |
| Cash used (since last report) | n/a | n/a | 1.34 mm | 2.19 mm | n/a | 868.53 k |
| Cash remaining | n/a | n/a | 21.80 mm | 20.95 mm | n/a | 22.27 mm |
| Runway (months of cash) | n/a | n/a | 33.2 | 19.5 | n/a | 52.3 |
Institutional ownership, Q4 2022
63.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 65 |
| Opened positions | 11 |
| Closed positions | 9 |
| Increased positions | 18 |
| Reduced positions | 14 |
| 13F shares | Current |
|---|---|
| Total value | 10.75 bn |
| Total shares | 47.20 mm |
| Total puts | 2.80 k |
| Total calls | 90.30 k |
| Total put/call ratio | 0.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Champion River Ventures | 7.94 mm | $9.77 mm |
| Pioneer Step | 6.92 mm | $8.51 mm |
| Shing Li Ka | 6.50 mm | $11.44 mm |
| Hoi Shuen Solina Holly Chau | 5.96 mm | $38.73 mm |
| Societe des Produits Nestle | 3.82 mm | $5.53 mm |
| Li Ka Shing | 3.47 mm | $12.97 mm |
| Tieton Capital Management | 2.75 mm | $4.61 mm |
| Vanguard | 2.61 mm | $4.38 bn |
| ICONIQ Capital | 1.30 mm | $2.18 bn |
| Phillip MD Frost Et Al | 1.23 mm | $11.82 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 May 23 | Rubin Steven D | Common Stock | Buy | Acquire P | No | No | 1.46 | 7,000 | 10.22 k | 7,000 |
| 15 Feb 23 | Fried Robert N | Employee Stock Options Common Stock | Grant | Acquire A | No | No | 1.82 | 306,366 | 557.59 k | 306,366 |
| 15 Feb 23 | Brianna Gerber | Employee Stock Options Common Stock | Grant | Acquire A | No | No | 1.82 | 163,996 | 298.47 k | 163,996 |
| 30 Sep 22 | Hoi Shuen Solina Holly Chau | Common Stock | Buy | Acquire P | Yes | No | 1.25 | 960,000 | 1.20 mm | 7,885,641 |
News
Recap: ChromaDex Q1 Earnings
10 May 23
ChromaDex Q1 EPS $(0.03) Beats $(0.05) Estimate, Sales $22.56M Beat $19.32M Estimate
10 May 23
Earnings Scheduled For May 10, 2023
10 May 23
HC Wainwright & Co. Maintains Buy on ChromaDex, Lowers Price Target to $5
13 Mar 23
ChromaDex Earnings Perspective: Return On Capital Employed
10 Mar 23
Press releases
ChromaDex to Participate in the LD Micro Invitational XIII
30 May 23
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
11 May 23
ChromaDex Corporation Reports First Quarter 2023 Financial Results
10 May 23
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
2 May 23
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results
8 Mar 23